The spread of a steroid-containing foam from the rectum was studied in eight normal controls and eight patients with ulcerative colitis proved by biopsy. A 
Introduction
The local application of corticosteroids has long been recognised to be of considerable value in treating patients with ulcerative colitis. In 1956 Truelove' described the intrarectal infusion of an alcoholic solution of hydrocortisone by means of a drip set and rubber catheter. This gave satisfactory results, which were improved further by using an aqueous solution of hydrocortisone hemisuccinate. In 1960 a prednisolone sodium phosphate enema was shown by Matts2 to be an effective treatment for colitis and simple to administer. In the same -trial a preliminary study was performed whereby 100 ml of dilute barium solution was substituted for the enema fluid. This showed that such an enema can spread a considerable way into the colon and often well beyond the splenic flexure, provided that the patient lies on his face for a few minutes after administration. Although effective, the prednisolone sodium phosphate enema has notable disadvantages. It is often uncomfortable, and many patients find it difficult to retain even when the foot of the bed is raised.
Recently a steroid-containing foam (Colifoam) We studied 16 subjects. Eight were medical staff or students (controls) who had no symptoms of bowel disease. Eight were patients who had ulcerative colitis proved by sigmoidoscopy and biopsy. All subjects gave informed consent in writing. At the time of the study all the patients with colitis were being managed as outpatients and their bowel habit varied from two to six loose stools per day.
The standard dose of foam was labelled as described above and placed in the rectum of each subject. Scans were performed at 15, 120, and 240 minutes in an anteroposterior plane in all subjects while they were prone on a couch. In addition, scans were performed in a lateral plane in three of the controls and four -of the patients with ulcerative colitis. All subjects were ambulant while not being scanned, and no restrictions were placed on food intake or bowel actions, although no subject found it necessary to defecate during the study. The extent. of spread of the foam was assessed by laying on the subject a Perspex rod containing technetium in small cavities at 2-5 cm intervals, the lower end of the rod being positioned at the level of the anus. This produced a series of graduations along the side of the scan, against which the length of the column of intrarectal activity was compared.
Results
Figures 3 and 4 represent two series of scans in two patients. Fig 3 shows 
Discussion
Our results indicate that using the foam results in a good topical application of steroid to the lower rectum but that more proximal spread is limited and infrequent. One criticism that could be put forward is that we made no attempt to ensure that the rectum was clear of any hard faecal matter that might prevent the spread of the foam. All the patients, however, had loose stools, and the foam spread no further in them than in the controls.
The aim of the study was simply to assess the extent of spread of the foam after rectal administration and not to attempt to compare the product with any other in terms of extent of spread or efficacy. Certain clinical implications, however, could not be avoided. On the basis of topical application alone the product is a rational treatment for only proctitis and mild distal ulcerative colitis. It would, however, seem illogical to use it for more proximal disease, and our clinical impression has been that under these circumstances it is less effective. If it is of benefit in more proximal disease this can be assumed to be only the result of absorption of the steroid from the foam by the rectal mucosa, any effect being that of systemic steroid. Of the clinical trials quoted by the manufacturer, only that of Scherl and Scherl4 attempted to differentiate between patients with proximal or distal disease. Unquestionably, however, the foam is more comfortable and easier to retain than a retention enema, and since the patient need not be immobilised, the foam obviously has a place in outpatient practice for patients with proctitis and distal ulcerative colitis.
We wish to thank Professor B Pullan for his advice, and Stafford Miller Limited for supplying the Colifoam.
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The findings suggest that it is no longer justifiable to prescribe a low-carbohydrate diet for maturity-onset diabetes.
Introduction
Since insulin became routinely available over 50 years ago there has been some relaxation in restricting dietary carbohydrate in diabetic clinics. Despite this, in 1971 most clinics in Great Britain were still recommending a low-carbohydrate diet (carbohydrate constituting about 40O0 of total daily energy) for both maturity-onset and insulin-requiring disease.' Increasing evidence suggests, however, that dietary carbohydrate is not detrimental to blood sugar control.2 An average carbohydratecontaining diet (carbohydrate providing 50-550o of total energy) gives a similar improvement in fasting blood sugar values to that obtained with the lower carbohydrate diet when recommended in newly diagnosed maturity-onset diabetes.3 Several workers4 5 have suggested that much higher carbohydrate-containing diets reduce the fasting blood sugar concentration. More recently it has been shown that increasing the dietary fibre,6 particularly guar or pectin, reduces the postprandial blood sugar concentration. These studies, however, used formula diets,4-6 unacceptably high amounts of carbohydrate,4 5 and carbohydrate foods likely to be unpalatable to some patients.-Furthermore, measures of diabetic control used were principally confined to fasting blood glucose and 24-hour urinary glucose values.
We therefore decided to examine in greater detail the effect in maturity-onset diabetes of an acceptable, high-carbohydrate diet composed of commercially available high-carbohydrate foods such as wholemeal bread and tuberous vegetables.
Patients and methods
Eighteen patients with established maturity-onset diabetes (15 men and three women) were recruited into the study. Their mean age (± SE of mean) was 54 +20 years and mean percentage of ideal body weight (±SE of mean; Metropolitan Life Assurance Co) 106 3 +33.
All were considered to be clinically and chemically stable (14 taking sulphonylureas and the remainder dietary treatment alone), their mean
